Home -> Law Blog Directory -> Personal Injury Law Blogs -> Philadelphia Personal Injury Lawyer
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Personal Injury Law
: Philadelphia Personal Injury LawyerGlaxoSmithKline Escapes Criminal Prosecution
By Jamie Sheller
Drugmaker, GlaxoSmithKline, escapes criminal prosecution in Britian, for withholding information about adverse effects of its drug, Seroxat. Seroxat, is marketed in the United States, as Paxil. According to Britian authorities, GlaxoSmithKline had information that Seroxat could increase sucidial thoughts in teens under the age of 18. However, GlaxoSmithKline did not release that information to the Healthcare Regulatory Agency until four years later. GlaxoSmithKline did not believe it had an obligation to notifiy the Agency of the problems since the drug was not approved for use by teens. Since that time, the laws have been changed to make it clear when drugmakers must report adverse events in any study conducted in the country. The Agency now seeks to change the law so that regardless of where a study takes the place, the drug maker must report its results.
Full post as published by Philadelphia Personal Injury Lawyer on March 10, 2008 (boomark / email).
Missing Children
Databases and organizations
Paxil Lawsuit
Paxil Claims, Lawsuits, and Injuries
Criminal Law
If you have been arrested or mistreated by police you should speak to a criminal law attorney.
GlaxoSmithKline Pays $750 Million Over Defective Drugs
GlaxoSmithKline Pays $750 Million Over Defective Drugs
Wal-Mart
Avoids Criminal Charges over Clerk's Death
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Drug Pusher
Biovail agrees to pay $24.6 million settlement in criminal lawsuit.

GlaxoSmithKline to Acquire Sirtris Pharmaceuticals; Solvay Tenders Offer for Innogenetics
New opinion on collateral estoppel in class action cases: Johnson v. GlaxoSmithKline, Inc.
Antitrust Suit against GlaxoSmithKline Certified Class Action
GlaxoSmithKline adds delirium, abnormal behavior warning to Relenza
ECJ: Judgment in Case Laboratoires Glaxosmithkline








